Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Promyelocytic, Acute 1

Interventions

Bevacizumab 4Zoledronic Acid 3Cisplatin 3Capecitabine 3spartalizumab 2anlotinib 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Metformin 2Letrozole 2Drug Therapy 2vosaroxin 1venetoclax 1tislelizumab 1pembrolizumab 1enzalutamide 1empagliflozin 1atezolizumab 1apatinib 1abiraterone 1XELOX 1Vacuum Curettage 1Tyrosine Kinase Inhibitors 1Tuberculin 1Sorafenib 1Sodium Chloride 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER_GOV × Lisaftoclax × Clear all
NCT07597941 2026-06-04

Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

The Affiliated People's Hospital of Ningbo University

Phase 2/3 Not yet recruiting
60 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡